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Background: Studies on the determinants of human papillomavirus (HPV) vaccine use have generally focused on
individual-level characteristics, despite the potentially important influence of regional-level characteristics. Therefore,
we undertook a population-based, retrospective cohort study to identify individual- and regional-level determinants
of HPV vaccine refusal (non-receipt) in Ontario’s (Canada) Grade 8 HPV Immunization Program.
Methods: Ontario’s administrative health and immunization databases were used to identify girls eligible for free HPV
vaccination in 2007–2011 and to ascertain individual-level characteristics of cohort members (socio-demographics,
vaccination history, health care utilization, medical history). The social and material characteristics of the girl’s region
(health unit) were derived from the 2006 Canadian Census. Generalized estimating equations (binomial distribution,
logit link) were used to estimate the population-average effects of individual- and regional-level characteristics on HPV
vaccine refusal.
Results: Our cohort consisted of 144,047 girls, 49.3% of whom refused HPV vaccination. Factors associated with refusal
included a previous diagnosis of Down’s syndrome (OR = 1.37, 95% CI 1.16-1.63) or autism (OR = 1.60, 95% CI 1.34-1.90),
few physician visits (OR = 1.45, 95% CI 1.35-1.55), and previous refusal of mandatory (OR = 2.23, 95% CI 2.07-2.40) and
optional (OR = 3.96, 95% CI 3.87-4.05) vaccines. Refusal was highest among the lowest and highest income levels.
Finally, a previous diagnosis of obesity and living in an area of high deprivation were associated with lower refusal
(OR = 0.87, 95% CI 0.83-0.92 and OR = 0.82 95%, CI 0.79-0.86, respectively).
Conclusions: Studies on HPV vaccine determinants should consider regional-level factors. Efforts to increase HPV
vaccine acceptance should include vulnerable populations (such as girls of low income) and girls with limited contact
with the healthcare system.
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The human papillomavirus (HPV) is the most common
sexually transmitted infection worldwide, with an esti-
mated 75% of all women having at least one HPV infec-
tion during their lifetime [1]. One of the most common
manifestation of HPV infections is genital warts, with a
prevalence of approximately 1-4% among young, sexually
active women [2]. Importantly, the presence of anogenital
warts can lead to significant physical, emotional, and social* Correspondence: linda.levesque@queensu.ca
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unless otherwise stated.problems for those affected [3]. While genital warts inflict
the greatest HPV-related burden on youth, HPV infections
may also lead to cancers of the anogenital tract in adult-
hood, the most frequent being cervical cancer. Of the over
100 types of HPV that have been identified, HPV types 6
and 11 cause 90% of cases of genital warts [4] and types
16 and 18 cause 70% of cases of cervical cancer worldwide
[5,6]. Overall, infections with these four HPV types repre-
sent a significant burden of illness and distress, and are es-
timated to cost the Canadian healthcare system $33
million annually [7].
In 2006, the quadrivalent HPV (qHPV) vaccine was ap-
proved for use in Canada, the United States, Europe, andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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public health implications of HPV-related diseases, the
Canadian government allocated $300 million to the prov-
inces and territories to fund the first three years of a na-
tional, school-based HPV vaccination program [9]. Despite
widespread anticipation about the vaccine’s potential to re-
duce the burden of anogenital warts and cervical cancer,
HPV vaccine coverage was generally lower than anticipated
in Canada, reaching nationwide lows of 50% in Alberta and
Manitoba, 53% in Ontario, and 65% in British Columbia
[10,11]. High refusal of the HPV vaccine has also been doc-
umented in a number of European and Indo-Pacific coun-
tries, the United States, and some Central and South
American countries [12].
Vaccine refusal falls within the spectrum of a growing
phenomenon recently referred to as “vaccine hesitancy”
[13]. Decision-making with respect to health behaviours,
including vaccination, has been shown to be complex,
and influenced by both individual- and regional-level
factors [14,15]. Indeed, the World Health Organization’s
(WHO) Strategic Advisory Group of Experts (SAGE) on
Immunization recently highlighted the importance of con-
textual factors including socio-cultural and environmental
ones, as determinants of vaccine hesitancy [13]. Yet, stud-
ies of the determinants of HPV vaccine uptake published
to date have focused predominantly on individual-level
characteristics, with little consideration for the potentially
important influence that an individual’s environment can
have on the decision-making process [16,17]. Given that
low vaccine coverage undermines public health efforts
aimed at reducing the burden of HPV-related diseases,
and may threaten the cost-effectiveness of HPV vaccin-
ation programs, we undertook a population-based, retro-
spective cohort study of girls eligible for Ontario’s Grade 8
HPV vaccination program to identify the individual- and
health unit-level determinants of HPV vaccine refusal.
Methods
This study was approved by the Research Ethics Board
of Queen’s University and Sunnybrook Health Sciences
Centre.
Ontario’s Grade 8 HPV vaccination program
Ontario’s HPV vaccination program was initiated in
September of 2007. This voluntary program offers three
doses of the vaccine free-of-charge to all Grade 8 girls
in the province. These doses are generally administered
by Public Health Nurses at school clinics in September/
October, November/December, and March/April to cor-
respond with the recommended 0-, 2-, and 6-month
dosing schedule of the vaccine. Although the vast ma-
jority of doses are given at these school clinics, eligible
girls may also receive the vaccine through their public
health unit or family physician. At the time of thisstudy, eligible girls had until the end of their Grade
9 year to complete the vaccination series, provided they
initiate it in Grade 8 [17]. All doses of the HPV vaccine
are documented in the Immunization Record Informa-
tion System (IRIS) database, regardless of where the
dose is administered. Over 80,000 girls are eligible for
this program each year.
Data sources and record linkage
Four administrative health databases were used for this
study: (1) the Registered Persons Database (RPDB) to
identify the birth cohorts and obtain information on
socio-demographics, (2) the Canadian Institute for Health
Information’s Discharge Abstract Database (CIHI-DAD)
for dates of hospital admissions and discharge diagnoses,
(3) the National Ambulatory Care Reporting System
(NACRS) for information on emergency department visit
dates and diagnoses, and (4) the Ontario Health Insurance
Plan (OHIP) database for information on fee-for-service
claims submitted by physicians, including service dates
and diagnoses. In these databases, each Ontario resident
covered by the province’s universal health insurance plan is
represented by a unique encrypted identifier that enables
complete record linkage at the level of the individual across
databases and over time. These databases are continuously
updated and can be accessed through the Institute for Clin-
ical Evaluative Sciences’ (ICES) satellite unit located at
Queen’s University. Described elsewhere in detail [18-22],
these databases have been used extensively in health re-
search, including studies of the HPV vaccine [23,24].
To obtain vaccination history, we used the IRIS database,
which was developed by the Ministry of Health and Long-
Term Care (MOHLTC) to assist the province’s 36 health
units in tracking and recording immunizations of school-
aged children, as required under the Immunization of
School Pupils Act (1982) [25]. This database is also used to
document the receipt of optional vaccines, including the
HPV vaccine. Indeed, the IRIS database has been shown to
accurately capture information on HPV vaccination status
with a sensitivity of 99.8% (95% CI: 99.3 - 99.9) and specifi-
city of 97.7% (95% CI: 96.3 - 98.7) [26]. At the time of this
study, the IRIS database of 21 health units had been trans-
ferred to ICES and were available for our use.
We also used data from the 2006 Canadian Census, a
mandatory, self-reported survey conducted every five
years by Statistics Canada to enumerate all residents of
Canada and provide a socio-demographic portrait of the
Canadian population. We used the Census database to
ascertain socio-demographic information at the level of
the health unit (i.e., regional-level characteristics) [27].
Study design and population
We identified a retrospective cohort of girls eligible for
Ontario’s Grade 8 HPV vaccination program between
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health records. Because a girl’s school grade was not
available in these data holdings, birth cohorts were used
to identify the eligible population. Since students typic-
ally turn thirteen by December 31 of their Grade 8
school year, girls born in 1994, 1995, 1996 and 1997,
would have been in Grade 8 in September 2007, 2008,
2009, and 2010, respectively, and would have been eli-
gible for the corresponding year’s vaccination program.
Although this approach could miss girls who were ad-
vanced or held back a grade, a re-abstraction study of a
medium-sized health unit demonstrated that this birth
cohort definition correctly identified 96.4% of eligible
girls [28]. Girls whose vaccination records were not
available at the time of the analysis (i.e., IRIS data not
yet transferred to ICES for record linkage) were ex-
cluded from the cohort. Cohort members were followed
from September 1 of their Grade 8 year until their date
of death or March 31, 2011 (study end).
HPV vaccination status
The outcome of interest was HPV vaccine non-receipt
(which we refer to as “refusal”), which was obtained from
the IRIS database. A girl was classified as a “refuser” if she
received no doses of the HPV vaccine; otherwise she was
classified as an “acceptor”.
Individual-level characteristics
We determined the socio-demographics, vaccination his-
tory, medical history, and health care utilization history of
cohort members using the administrative health and
immunization databases previously described. The RPDB
was used to obtain information on age, sex, neighbourhood
income quintile, and urban/rural residency at cohort entry.
Vaccination history was derived from the IRIS database
and included vaccinations received from birth to cohort
entry. The optional vaccines under consideration were
hepatitis B and meningococcal conjugate because they are
both offered in Grade 7 through a publicly funded, school-
based program. Mandatory vaccines included the measles,
mumps, rubella (MMR) vaccine, as well as the diphtheria,
polio, and tetanus (DTP) vaccine. Vaccination history, par-
ticularly with optional vaccines, was used as a proxy for
parental/guardian beliefs and attitudes toward vaccines in
general.
Medical and health care utilization histories of cohort
members were obtained between birth and cohort entry
using the physician services (OHIP), emergency department
(NACRS), and hospital (CIHI-DAD) databases. The med-
ical conditions considered included those resulting in fre-
quent contact with the health care system, as well as those
serious enough to potentially affect the decision to vaccin-
ate against HPV (e.g., autoimmune disorders, cancer, con-
genital anomalies, heart disease, neurological disease;Additional file 1). Health care utilization was determined
based on the number of outpatient physician visits, emer-
gency department visits, hospital admissions, and in-patient
length of stay prior to cohort entry. The frequency of each
type of utilization was categorized based on the frequency
distribution of the data. These categories were used as indi-
cators of an individual’s health status and their propensity
to use the health care system.
Characteristics of the health units
The 2006 Canadian Census was used to obtain informa-
tion on the social and material characteristics of the
health unit within which a cohort member resided at co-
hort entry. We used information from the 2006 Census
since this represented the latest data available prior to
cohort entry (i.e., preceding the decision to vaccinate).
Since health units are responsible for the administration
and delivery of the HPV vaccination program in Ontario,
the health unit was chosen as the regional level of interest
for this study. Based on a review of the literature on the
determinants of HPV vaccine acceptance, we initially con-
sidered 19 census variables (Additional file 2). We exam-
ined the variability of these characteristics across health
units, the collinearity between variables, and each vari-
able’s univariable association with the outcome. Based on
these analyses, we determined that only six of these char-
acteristic warranted further consideration - average in-
come, level of education, employment/population ratio,
marital status, and living alone.
To further address the potential for collinearity between
indicators, as well as to reduce the number of variables
contributing to the model (given the limited number of
health units contributing to the analysis), we developed an
area deprivation index. The index was modelled after the
Pampalon social and material deprivation index [29] and
was derived using principal component analysis (PCA)
[30]. Although we included the same six social and mater-
ial factors contained in the Pampalon index in our PCA,
only five loaded as a component/dimension and were thus
included in our index; single parenthood was not consid-
ered further (Additional file 3). A score was calculated for
each health unit based on the factor loadings of each of
the five indicators. For the purposes of analysis, these
scores were subsequently categorized into quartiles.
Statistical analysis
To estimate the population average effect of the deter-
minants of interest on HPV vaccine refusal, we used
generalized estimating equations (GEE) to account for
the correlation introduced by the clustering of individ-
uals within health units. The characteristics of the health
unit were attributed to the girl, making her the unit of
analysis. Since the outcome was dichotomous (refusal vs.
non-refusal), and the correlation between subjects in
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a logit link and an exchangeable correlation structure to
estimate odds ratios (ORs) and 95% confidence intervals
(CIs; based on robust standard errors). The final model
was selected using backward selection and a significance
threshold of 0.1 for variable retention.
Results
Within the 21 health units, we identified 144,047 girls
eligible for Ontario’s Grade 8 HPV vaccination program
between 2007/08 and 2010/11. Girls were a mean of
13.2 years of age at cohort entry and were followed for
an average of 2.6 years. Approximately 3% of cohort
members refused MMR and/or DTP vaccination and
42% refused hepatitis B and/or meningococcal conju-
gate vaccination (Table 1). Almost 65% of girls resided
in areas of low material and social deprivation.
The average number of cohort members per health unit
was 6859 (range: 1012–18171). Overall, 49.3% (n = 71,048)
of cohort members refused HPV vaccination during the
study period; refusal varied from 41.8% to 60.3% across
health units. While absolute differences were small, neigh-
bourhood income quintile was a statistically significant de-
terminant of HPV vaccine refusal, with the highest level of
refusal in the highest and lowest quintiles (Table 2).
Immunization history was also a determinant of HPV vac-
cination in that HPV vaccine refusal was more common
among girls who had not received optional and mandatory
immunizations in the past (OR = 3.96, 95% CI 3.87-4.05;
OR = 2.23, 95% CI 2.07-2.40, respectively). Refusal was gen-
erally similar across categories of health care utilization and
history of a serious medical condition, but there were some
exceptions. In particular, there was a dose–response trend
with respect to physician visits, whereby girls with the low-
est level of contact with a physician were the most likely to
refuse HPV vaccination (OR = 1.45, 95% CI 1.35-1.55) and
refusal decreased with increasing levels of physician visits
(p < 0.05). In addition, parents/guardians of girls with a his-
tory of autism or Down’s syndrome appeared more likely to
refuse HPV vaccination than caregivers with unaffected
children (OR= 1.60, 95% CI 1.34-1.90; OR = 1.37, 95% CI
1.16-1.63, respectively). In contrast, obesity was associated
with decreased refusal (OR = 0.87, 95% CI 0.83-0.92).
Finally, health unit-level social and material deprivation was
associated with HPV vaccine decision-making, with the low-
est refusal observed among girls living in regions with the
highest level of deprivation (OR= 0.82, 95% CI 0.79, 0.86).
Discussion
Nearly half of all girls eligible for Ontario’s free HPV vac-
cination program between the 2007/08 and 2010/11
school year did not receive the vaccine. Our study showed
that factors related to this high level of refusal included
previous diagnoses of Down’s syndrome or autism, as wellas low income and high income, and infrequent visits to
the doctor. Interestingly, obesity and high area deprivation
were determinants of HPV vaccine acceptance. Not sur-
prisingly, a history of vaccine refusal was also associated
with refusal of the HPV vaccine.
This study is one of the first to consider medical history
as a potential determinant of HPV vaccine use. We found
that a history of an obesity-related diagnosis was associated
with increased HPV vaccine acceptance. As studies indicate
there is an important association between obesity and cer-
vical cancer [31], these results are promising as they suggest
that this high risk group is receiving protection against cer-
vical cancer. Nevertheless, given then limited information
on this topic, these results need to be confirmed.
This study also found that girls with Down’s syndrome
or autism were less likely to receive the HPV vaccine than
girls who have not been diagnosed with these intellectual
disabilities (IDs). However, we used birth year to estimate
the girls’ grade 8 school year, and since individuals with
IDs are more likely to start school late or be held back
school grades [32], it is possible the association we ob-
served merely reflects the fact that these girls were not yet
eligible for publicly funded vaccination. Some individuals
with IDs may be homeschooled [33], which would limit
their access to the school-based vaccination program.
Moreover, there is a common misconception that individ-
uals with IDs are less sexually active than their peers
[34,35], which may lead caregivers to perceive HPV
immunization as less necessary for these children. In real-
ity, however, adolescents with IDs report similar ages of
sexual onset and rates of sexual activity as their typically
developing peers [34,35] and are at higher risk of sexual
abuse [36], suggesting they are at a similar (if not higher)
risk of HPV-related illnesses. As a result, this association
should be further investigated. Regardless, our study high-
lights the importance of considering medical history in
studies on the HPV vaccine as potential determinants of
HPV vaccine use and as potential confounders of the ef-
fects of HPV vaccination.
We also found that HPV vaccine acceptance increased
with increased levels of outpatient contacts with a phys-
ician. These results are consistent with studies from the
United States that demonstrate the important, positive in-
fluence physicians can have on increasing HPV vaccine ac-
ceptance among parents and women [16,37,38]. Our study
suggests that this relationship holds even in the context of
a publicly funded, school-based program, where the vac-
cine is primarily delivered outside of the physician’s office.
Nevertheless, it is important to recognize that increased
number of physician visits may also be a proxy for paren-
tal health beliefs and behaviours, which likely also influ-
ence HPV vaccine receipt.
Our study is also one of the first to consider both
individual-level and regional-level characteristics as

















Refusal of mandatory vaccines* 4,160 (2.9)





















Congenital anomalies 4,723 (3.3%)
Viral diseases 95,070 (66.0%)
Cardiovascular disease 26,620 (18.5%)
Obesity 6,264 (4.4%)
Autism 599 (0.42%)
Mental illness 44,588 (31.0%)
Neurological diseases 12,972 (9.0%)
Table 1 Baseline characteristics of cohort members
(N = 144,047) (Continued)
Down’s syndrome 639 (0.4%)
Diseases of the musculoskeletal system 48,670 (33.8%)
Respiratory disease 63,250 (43.9%)
Diseases of the endocrine system 5,460 (3.8%)
In-situ carcinoma and benign lesions 13,649 (9.5%)
Cancer 2,491 (1.7%)
Malnutrition 6,558 (4.5%)
Immune-mediated disorders 100,874 (70.0%)
Health unit-level characteristics
Index of area deprivation (quartiles)
1st (low) 93,093 (64.6)
2nd 21,249 (14.6)
3rd 18,482 (12.8)
4th (high) 11,223 (7.8)
*Includes measles, mumps, rubella (MMR) and diphtheria, tetanus, pertussis
(DTP) vaccines.
†Includes hepatitis B and meningococcal conjugate vaccines.
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Interestingly, we found that girls living in areas of high
deprivation were more likely to receive the HPV vaccine
than girls living in areas of low deprivation. Our results
are not consistent with studies from the United States,
which report that indicators of deprivation (e.g., low
income, low education) are major barriers to HPV vaccin-
ation [16]. The latter findings are not surprising given the
high cost of the vaccine series (~$450 CND) and the lack of
publicly funded vaccination, but are of particular public
health importance as these indicators of deprivation are
also major risk factors for cervical cancer [39,40]. Accord-
ingly, our results suggest the publicly funded, school-based
nature of the HPV vaccination programs in Canada is help-
ing to reduce inequities in access to the HPV vaccine that
may ultimately help reduce inequities in HPV-related ill-
nesses. Further studies are needed to corroborate these
findings.
Importantly, our findings on area deprivation were in-
dependent of our one individual-level component of
deprivation – family income. Indeed, income was asso-
ciated with HPV vaccine refusal, whereby girls in the
highest and lowest income quintiles were the most
likely to refuse HPV vaccination. Our finding of high re-
fusal among higher income families is consistent with a
study from British Columbia (Canada) that found that
parents of higher socio-economic status (SES) were less
likely to accept having their daughters vaccinated, des-
pite being more informed about the benefits of the HPV
vaccine [41]. Similarly, studies have consistently re-
ported that low income is associated with high refusal
[16]. However, most of these studies were conducted in
Table 2 Determinants of HPV vaccine refusal
Characteristic Refusal n (%) Unadjusted OR (95% CI) Adjusted† OR (95% CI)
Individual-level characteristics
Income quintiles*
1st (low) 21,357 (51.6) 1.24 (1.20, 1.29) 1.13 (1.09, 1.17)
2nd 25,689 (47.3) 1.04 (1.01, 1.08) 1.01 (0.98, 1.05)
3rd (reference) 30,823 (46.2) 1.00 1.00
4th 32,495 (48.3) 1.09 (1.05, 1.12) 1.12 (1.08, 1.15)
5th (high) 30,803 (49.7) 1.15 (1.11, 1.18) 1.21 (1.17, 1.25)
Vaccination history
Refusal of mandatory vaccines
No (reference) 139,887 (48.5) 1.00 1.00
Yes 4,160 (78.8) 3.95 (3.66, 4.26) 2.23 (2.07, 2.40)
Refusal of optional vaccines
No (reference) 83,600 (34.8) 1.00 1.00
Yes 60,447 (69.4) 4.25 (4.16, 4.35) 3.96 (3.87, 4.05)
Health care utilization
Hospitalizations
≤1 (reference) 110,167 (48.3) 1.00 1.00
2-4 29,350 (49.5) 0.95 (0.93, 0.98) 0.94 (0.91, 0.97)
≥4 4,530 (52.6) 1.13 (1.07, 1.20) 0.96 (0.90, 1.03)
Emergency department visits
None (reference) 48,413 (50.7) 1.00 1.00
1-4 69,796 (48.9) 0.93 (0.91, 0.95) 1.03 (1.01, 1.06)
5-12 21,229 (47.9) 0.89 (0.87, 0.92) 1.02 (0.98, 1.06)
≥13 4,609 (47.3) 0.87 (0.82, 0.93) 0.99 (0.93, 1.06)
Outpatient physician visits
≤42 36,861 (55.3) 1.55 (1.46, 1.64) 1.45 (1.35, 1.55)
43-116 74,797 (47.9) 1.15 (1.09, 1.22) 1.24 (1.17, 1.32)
117-206 26,794 (46.1) 1.07 (1.01, 1.14) 1.12 (1.05, 1.19)
≥207 (reference) 5,595 (44.4) 1.00 1.00
Medical history
Congenital anomalies
No (reference) 139,324 (49.3) 1.00 1.00
Yes 4,723 (50.2) 1.04 (0.98, 1.10) 1.03 (0.97, 1.10)
Viral diseases
No (reference) 48,977 (52.4) 1.00 1.00
Yes 95,070 (47.8) 0.83 (0.81, 0.85) 0.96 (0.94, 0.99)
Cardiovascular disease
No (reference) 117,427 (49.5) 1.00 1.00
Yes 26,620 (48.5) 0.96 (0.93, 0.98) 1.03 (1.00, 1.06)
Obesity
No (reference) 137,783 (49.5) 1.00 1.00
Yes 6,264 (45.0) 0.83 (0.79, 0.88) 0.87 (0.83, 0.92)
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Autism
No (reference) 143,448 (49.3) 1.00 1.00
Yes 599 (64.3) 1.85 (1.57, 2.19) 1.60 (1.34, 1.90)
Mental illness
No (reference) 99,459 (49.2) 1.00 1.00
Yes 44,588 (49.5) 1.01 (0.99, 1.04) 1.04 (1.01, 1.07)
Neurological disorder
No (reference) 131,075 (49.3) 1.00 1.00
Yes 12,972 (49.7) 1.01 (0.98, 1.05) 1.06 (1.02, 1.10)
Down’s syndrome
No (reference) 143,408 (49.3) 1.00 1.00
Yes 639 (60.6) 1.58 (1.35, 1.85) 1.37 (1.16, 1.63)
Health unit-level characteristics
Index of area deprivation (quartiles)
1st (low) (reference) 93,093 (49.8) 1.00 1.00
2nd 21,249 (48.9) 0.97 (0.94, 0.99) 1.02 (0.99, 1.06)
3rd 18,482 (49.2) 0.98 (0.95, 1.01) 1.01 (0.97, 1.05)
4th (high) 11,223 (46.4) 0.87 (0.84, 0.91) 0.82 (0.79, 0.86)
OR: odds ratio; 95% CI: 95% confidence interval.
*Of the 2,880 girls with a missing postal code (and, consequently, income quintile), 92% were classified as refusers. This high percentage most likely reflects
emigration from Ontario rather than actual refusal.
†Adjusted for all other factors listed in the table.
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barriers exist. Since financial and access barriers are
greatly reduced in countries, like Canada, that offer the
HPV vaccine free of charge, our findings suggest that
low income may be a proxy for other factors that influ-
ence vaccine acceptance in this population. Neverthe-
less, given the increased vulnerability of girls from low
income families to HPV-related diseases (as described
above), our findings demonstrate that this continues to
be an important group for targeted cervical cancer risk
education even in the context of publicly funded vaccin-
ation programs.
Finally, we found that HPV vaccine refusal was highest
among girls whose parents/guardians had also refused the
MMR, DTP, hepatitis B, and meningococcal conjugate vac-
cines. These findings are consistent with previous studies
on factors influencing HPV vaccine acceptance [16,23,41]
suggesting that caregiver knowledge, values and beliefs re-
garding vaccination may be a universal determinant of
HPV vaccine acceptance, independent of girls’ medical his-
tory, health care utilization, and characteristics of the envir-
onment in which she lives.
Our study has a number of strengths, including that it
benefits from a large, representative sample and validated
HPV vaccination data. Nevertheless, there are also a num-
ber of limitations that should be considered. First, the fac-
tors available for analysis were restricted to those captured
by administrative health databases and the CanadianCensus. As a result, residual confounding may have been
introduced if important determinants were not included in
the analysis. In addition, given that we did not have
information on individual-level deprivation, we cannot be
certain that area deprivation is a determinant of HPV vac-
cine refusal independent of individual-level deprivation.
However, our analysis did account for one important com-
ponent of individual-level deprivation (i.e., family income),
and area deprivation remained an independent predictor.
Another limitation is that a girl’s vaccination status would
have been misclassified as “refused” if she moved outside of
the 21 participating health units during study follow-up
and subsequently received her first dose of the vaccine else-
where. However, given most girls who initiate their vaccin-
ation series do so within the first few months following
cohort entry, this proportion is likely to be very low. It is
also important to recognize that, given the high prevalence
of the outcome (vaccine refusal), the odds ratios over-
estimate the risk ratios. Finally, the generalizability of our
results to jurisdictions is unknown.
Conclusion
Our study highlights the importance of including char-
acteristics of both the girl and her environment when
carrying out studies on HPV vaccination. In addition,
our results indicate that certain medical conditions
should be further investigated as potential determinants
of HPV vaccine use and as potential confounders of the
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the positive impact physicians may have on HPV vaccine
use, even in the context of a publicly funded system,
suggesting physicians could play a particularly valuable
role in HPV vaccine educational efforts.
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